Your browser doesn't support javascript.
loading
Persistent longitudinal T cell responses after SARS-CoV-2 mRNA vaccines in MS patients on different disease modifying treatments.
Disanto, Giulio; Galante, Alice; Sacco, Rosaria; Mallucci, Giulia; Mele, Federico; Sallusto, Federica; Zecca, Chiara; Gobbi, Claudio.
Afiliación
  • Disanto G; Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Galante A; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Sacco R; Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Mallucci G; Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Mele F; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland; Institute of Microbiology, ETH Zurich, 8093 Zurich, Switzerland.
  • Zecca C; Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
  • Gobbi C; Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland. Electronic address: claudio.gobbi@eoc.ch.
Mult Scler Relat Disord ; 90: 105813, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39154595
ABSTRACT
Few data are available regarding vaccine induced SARS-CoV-2 specific T cell responses over time and after booster doses in multiple sclerosis (MS) patients on different disease modifying treatments. We measured SARS-CoV-2 specific CD4+ T cell responses in 72 samples collected from 36 MS patients. The percentage of CD4+ CTVlow CD25+ ICOS+ T cells after stimulation with Spike Recombinant Protein was 29.9 (17.0-43.6) on teriflunomide, 32.4 (11.9-42.5) on ocrelizumab, but much lower (0.6 [0.3-5.9]) on sphingosine-1-phospate receptor modulators (ß = -26.35, p = 0.003). SARS-CoV-2 specific T cells were mainly of Th1 type and stable over time and after booster vaccine doses. mRNA vaccines elicit strong and persistent CD4+ T cell responses against SARS-CoV-2 in MS patients on anti-CD20 and teriflunomide, but not in those on sphingosine-1-phospate receptor modulators.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Esclerosis Múltiple / Nitrilos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Relat Disord Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Esclerosis Múltiple / Nitrilos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Relat Disord Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Países Bajos